Spur Therapeutics News and Activities

Spur Therapeutics is owned by Syncona.

Syncona is one of the...

• FTSE 350;
• TOB Iconic 10,000.

Syncona is a company listed under the stock ticker SYNC (GB).

Syncona has a direct presence in 3 countries.

Syncona has 11 subsidiaries including Anaveon, Autolus Therapeutics and Beacon Therapeutics.

They are in:

• Biotechnology83%
• Holding8%
• Other8%

View the org chart displaying its 22 main executives

Most searched biographies at Spur Therapeutics

• Michael Parini, Chief Executive Officer and Executive Director (be...
• Samantha Roberts, Director
• Chris Hollowood, Chairman of the Board (becomes Director on Aug 1 ...

Popular executive movements at Spur Therapeutics

• Samantha Roberts who is Executive Partner, Syncona, will become Director on Jul. 31, 2026  (posted on July 17 2026).
• Henning Stennicke who is Chief Scientific Officer, will become Chief Operating Officer on Aug. 1, 2026  (posted on July 15 2026).
• Michael Parini who is Chief Executive Officer and Executive Director, will become Chairman of the Board on Aug. 1, 2026  (posted on July 15 2026).

Click here to view some more movements at Spur Therapeutics

Popular executive movements at Syncona

• Norman Crighton will join the company as Independent Non-Executive Director on Jul. 1, 2026  (posted on June 17 2026).

Create your alert
to follow the executive moves at Spur Therapeutics.

Syncona has 2,429 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Eli Lilly has announced the acquisition of AtaiBeckley  (posted on July 17 2026).
• GSK has acquired Nuvalent (posted on July 17 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (posted on July 15 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Spur Therapeutics

• Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1
• Spur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD 2026 Symposium
• Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™
• Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium™
• Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress
• Spur Therapeutics to Present New Clinical Data on Its Gene Therapy Candidate in Gaucher Disease at Upcoming ESGCT Annual Congress
• Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting
• Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease
• Spur Therapeutics Announces Oral and Poster Presentations Highlighting Data from Clinical and Preclinical Programs at Upcoming ASGCT Annual Meeting
• Spur Therapeutics to Participate in Citizens JMP 2025 Life Sciences Conference
• View more press releases Close

Social media about Spur Therapeutics

• Spur Therapeutics on Wikipedia, Google News & Yahoo Finance
• Spur Therapeutics on LinkedIn, X (Twitter) & YouTube